Quriviq (daridorexant) is not yet available in Canada. Health Canada has not approved the drug for use in the country.
When might Quriviq be available in Canada?
The timeline for Quriviq's availability in Canada depends on Health Canada's review and approval process. There is no publicly announced date for a decision.
What is Quriviq used for?
Quriviq is a medication used to treat insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [1]. It works by blocking the wake-promoting neurotransmitter orexin [1].
Has Quriviq been approved in other countries?
Quriviq has been approved by the U.S. Food and Drug Administration (FDA) and is available in the United States [1]. It has also received approval in Europe.
What are the potential side effects of Quriviq?
Common side effects of Quriviq can include sleep paralysis, unusual dreams, and headache [1]. It is important to discuss any potential side effects with a healthcare professional.
Are there alternatives to Quriviq for insomnia?
Yes, there are various treatment options for insomnia, including other prescription medications, cognitive behavioral therapy for insomnia (CBT-I), and lifestyle adjustments [2].
What is the mechanism of action for Quriviq?
Quriviq is a dual orexin receptor antagonist. Orexin is a neuropeptide that plays a key role in promoting wakefulness. By blocking orexin receptors, Quriviq reduces the signaling that keeps a person awake, thereby facilitating sleep [1].
Who developed Quriviq?
Quriviq was developed by Idorsia Pharmaceuticals [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.sleepfoundation.org/